Patents by Inventor Kwok Yung Yuen
Kwok Yung Yuen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160184421Abstract: The subject invention pertains to vaccine formulations and antibodies, and related methods, for the treatment and/or prevention of S. aureus infection. The present invention provides one or more S. aureus antigens for use in vaccine formulations, wherein two or more antigens act synergistically. Further, the present invention provides vaccines that can protect against hematic spread, pneumonia and skin infection.Type: ApplicationFiled: December 18, 2015Publication date: June 30, 2016Inventors: Jian-Dong Huang, Kwok-Yung Yuen, Baozhong Zhang
-
Publication number: 20160136261Abstract: The subject invention pertains to attenuated influenza viruses, and related vaccines and methods, comprising a genetically modified viral genome. The genetically modified viral genome comprises a disruption in the non-structural (NS1) coding segment and one or more base substitution in the matrix membrane protein coding segment. The genetic modifications result in viruses that lose NS1 functionality, yet remain replication competent.Type: ApplicationFiled: November 13, 2015Publication date: May 19, 2016Inventors: Honglin Chen, Min Zheng, Kwok-Yung Yuen
-
Patent number: 9212177Abstract: Compounds which exhibit antiviral activity, particularly against influenza virus, and methods of making and using thereof are described herein. In one embodiment, the compounds are heterocyclic amides containing piperazine and isozazole rings and optionally substituted with one or more substituents. The compounds can be formulated with one or more pharmaceutically acceptable excipients to form compositions suitable for enteral or parenteral administration. The compounds are preferably used to treat or prevent Influenza A infections, such as H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, and H10N7.Type: GrantFiled: August 5, 2010Date of Patent: December 15, 2015Assignee: Versitech LimitedInventors: Yi Tsun Richard Kao, Dan Yang, Kwok-Yung Yuen
-
Patent number: 9139620Abstract: Described herein are isolated paramyxovirus, a morbillivirus (FmoPV), nucleic acid molecules, polypeptides and antibodies related to FmoPV and uses thereof. In certain embodiments, the FmoPV is a feline morbillivirus. Also described herein is a recombinant FmoPV comprising a modified FmoPV gene or gene segments and uses thereof. Also described is a recombinant FmoPV for the prevention and/or treatment of diseases related to FmoPV or a delivery vector. Also described herein is a diagnostic assay for FmoPV, natural or artificial variants, analogs, or derivatives thereof. Also described herein is a vaccine and a kit containing the vaccine for the prevention and treatment of FmoPV infection. Also provided is a diagnostic kit comprising nucleic acid molecules for the detection of FmoPV.Type: GrantFiled: January 22, 2013Date of Patent: September 22, 2015Assignees: THE GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, VERSITECH LIMITEDInventors: Kwok-Yung Yuen, Patrick Chiu-Yat Woo, Susanna Kar-Pui Lau
-
Publication number: 20140155478Abstract: Disclosed herein is a novel antifungal compound, derivatives that are used to treat fungal infections. In a specific embodiment, the compound is a small molecule. In a specific embodiment, the compound described herein inhibits yeast to hypha transition under robust hyphal inducing conditions at lower concentration of the molecule. Also disclosed is a composition comprising the antifungal compound. In a specific embodiment, the composition is a pharmaceutical composition. Also disclosed is a method of treating and/or preventing fungal infection using the disclosed compound. The disclosed compound exhibits antifungal activity against wide range of fungal species at slightly higher concentrations. Antifungal compound disclosed herein is used as anti-biofilm agent against fungal infections.Type: ApplicationFiled: December 3, 2013Publication date: June 5, 2014Applicant: The University of Hong KongInventors: Chaminda Jayampath SENEVIRATNE, Yi Tsun Richard KAO, Lakshman Perera SAMARANAYAKE, Kwok Yung YUEN, Dan YANG, Yu WANG, Sze Wah Sarah WONG
-
Publication number: 20130230529Abstract: Described herein are isolated paramyxovirus, a morbillivirus (FmoPV), isolated nucleic acids encoding the genome of FmoPV, isolated amino acid sequences of FmoPV proteins, antibodies to FmoPV and its proteins, and uses thereof. In certain embodiments, the modified FmoPV is a feline morbillivirus. Also described herein is a recombinant FmoPV comprising a modified FmoPV gene or gene segments and the use of such a virus. The recombinant FmoPV may be used in the prevention and/or treatment of diseases related to FmoPV or as a delivery vector. Also described herein is a diagnostic assay for the FmoPV. In certain embodiments, the FmoPV causes kidney disease. In certain embodiments, the kidney disease is in felines. In certain embodiments, the kidney disease is tubulointerstitial nephritis (“TIN”). Also described herein is a quantitative assay for the detection of the FmoPV, natural or artificial variants, analogs, or derivatives thereof.Type: ApplicationFiled: January 22, 2013Publication date: September 5, 2013Applicant: The University of Hong KongInventors: Kwok-Yung Yuen, Patrick Chiu-Yat Woo, Susanna Kar-Pui Lau
-
Patent number: 8361708Abstract: The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences.Type: GrantFiled: February 10, 2010Date of Patent: January 29, 2013Assignee: Versitech LimitedInventors: Joseph S. M. Peiris, Kwok Yung Yuen, Lit Man Poon, Yi Guan, Kwok Hung Chan, John M. Nicholls, Frederick C. Leung
-
Publication number: 20120149715Abstract: High throughput and virtual screening methods are disclosed that can identify potential anti-viral agents. The virtual screening methods identify agents that interact with a viral nucleoprotein binding site. The high throughput methods identify compounds that inhibit viral infection by binding to viral nucleoprotein. Also disclosed are pharmaceutical formulations useful for treating or preventing viral infections, especially influenza A.Type: ApplicationFiled: May 31, 2011Publication date: June 14, 2012Inventors: Yi Tsun Richard Kao, Kwok-Yung Yuen, Dan Yang, Lihong Hu, Guanhua Chen, Bo-Jian Zheng
-
Publication number: 20120142701Abstract: Cell-based and cell-free assays are disclosed that detect compounds that promote aggregation of proteins, glycoproteins, and protein-nucleic acid complexes. Also disclosed are pharmaceutical formulations useful for treating or preventing viral infections, bacterial infections, cancer, and diseases involving hyper-proliferative cells.Type: ApplicationFiled: May 31, 2011Publication date: June 7, 2012Inventors: Yi Tsun Richard Kao, Kwok-Yung Yuen
-
Patent number: 8092994Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen, China. The virus belongs to the order Nidovirales of the family Coronavirdae, being a single-stranded RNA virus of positive polarity. The invention also provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.Type: GrantFiled: June 1, 2009Date of Patent: January 10, 2012Assignee: Versitech LimitedInventors: Kwok Yung Yuen, Chiu Yat Patrick Woo, Kar Pui Susanna Lau, Kwok Hung Chan, Lit Man Poon, Joseph Sriyal Malik Peiris, Yi Guan
-
Publication number: 20110212975Abstract: Compounds which exhibit antiviral activity, particularly against influenza virus, and methods of making and using thereof are described herein. In one embodiment, the compounds are heterocyclic amides containing piperazine and isozazole rings and optionally substituted with one or more substituents. The compounds can be formulated with one or more pharmaceutically acceptable excipients to form compositions suitable for enteral or parenteral administration. The compounds are preferably used to treat or prevent Influenza A infections, such as H1N1, H2N2, H3N2, H5N1, H7N7, H1N2, H9N2, H7N2, H7N3, and H10N7.Type: ApplicationFiled: August 5, 2010Publication date: September 1, 2011Inventors: Yi Tsun Richard Kao, Dan Yang, Kwok-Yung Yuen
-
Publication number: 20100285457Abstract: The present invention relates to a high-throughput diagnostic assay for the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). In particular, the invention relates to a high-throughput reverse transcription-PCR diagnostic test for SARS associated coronavirus (SARS-CoV). The present assay is a rapid, reliable assay which can be used for diagnosis and monitoring the spread of SARS and is based on the nucleotide sequences of the N (nucleocapsid)-gene of the hSARS virus. The present method eliminates false negative results and provides increased sensitivity for the assay. The invention also discloses the S (spike)-gene of the hSARS virus. The invention further relates to the deduced amino acid sequences of the N-gene and S-gene products of the hSARS virus and to the use of the N-gene and S-gene products in diagnostic methods. The invention further encompasses diagnostic assays and kits comprising antibodies generated against the N-gene or S-gene product.Type: ApplicationFiled: June 12, 2009Publication date: November 11, 2010Inventors: Joseph S.M. Peiris, Kwok Yung Yuen, Lit Man Poon, Yi Guan, Kwok Hung Chan, John M. Nicholls, Frederick C. Leung
-
Patent number: 7785775Abstract: The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences.Type: GrantFiled: June 8, 2007Date of Patent: August 31, 2010Assignee: Versitech LimitedInventors: Joseph Sriyal Malik Peiris, Kwok Yung Yuen, Lit Man Poon, Yi Guan, Kwok Hung Chan, John M. Nicholls, Frederick C. Leung
-
Publication number: 20100184019Abstract: The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences.Type: ApplicationFiled: February 10, 2010Publication date: July 22, 2010Inventors: Joseph S.M. Peiris, Kwok Yung Yuen, Lit Man Poon, Yi Guan, Kwok Hung Chan, John M. Nicholls, Frederick C. Leung
-
Publication number: 20100080824Abstract: The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences.Type: ApplicationFiled: June 8, 2007Publication date: April 1, 2010Applicant: The University of Hong KongInventors: Joseph S.M. Peiris, Kwok Yung Yuen, Lit Man Poon, Yi Guan, Kwok Hung Chan, John M. Nicholls, Frederick C. Leung
-
Publication number: 20090305282Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen. China. The virus belongs to the order Nidovirales of the family Coronavirdae, being a single-stranded RNA virus of positive polarity. The invention also provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.Type: ApplicationFiled: June 1, 2009Publication date: December 10, 2009Inventors: KWOK YUNG YUEN, CHIU YAT PATRICK WOO, KAR PUI SUSANNA LAU, KWOK HUNG CHAN, LIT MAN POON, JOSEPH SRIYAL MALIK PEIRIS, YI GUAN
-
Patent number: 7605135Abstract: The present invention relates to a pharmaceutical composition useful for the treatment of diseases associated with viruses of the order Nidovirales of the family Coronaviradae, such as Severe Acute Respiratory Syndrome (SARS) viruses in humans and other animals. In particular, this invention relates to a naturally occurring compound, namely, baicalin, extracted and purified from the Chinese medicinal plant Scutellaria baicalensis Georgi (Chinese name: Huang Qin), that exhibits potent antiviral activity against members of the order Nidovirales of the family Coronaviradae that infects humans and other animals; in particular, SARS viruses in humans (“hSARS virus”). The invention also relates to a therapeutic method, using pharmaceutical compositions comprising baicalin compounds, for the treatment, amelioration, management or prevention of diseases associated with members of the order Nidovirales of the family Coronaviradae, such as hSARS.Type: GrantFiled: November 8, 2004Date of Patent: October 20, 2009Assignee: The University of Hong KongInventors: Kwok Yung Yuen, Feng Chen, Kwok Hung Chan, Yi Tsun Kao, Yi Guan, Leo Lit Man Poon, JSM Peiris
-
Patent number: 7553944Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen, China. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RNA virus of positive polarity. The invention also provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.Type: GrantFiled: July 21, 2004Date of Patent: June 30, 2009Assignee: The University of Hong KongInventors: Kwok Yung Yuen, Chiu Yat Patrick Woo, Kar Pui Susanna Lau, Kwok Hung Chan, Lit Man Poon, Joseph Sriyal Malik Peiris, Yi Guan
-
Patent number: 7547512Abstract: The present invention relates to a high-throughput diagnostic assay for the virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). In particular, the invention relates to a high-throughput reverse transcription-PCR diagnostic test for SARS associated coronavirus (SARS-CoV). The present assay is a rapid, reliable assay which can be used for diagnosis and monitoring the spread of SARS and is based on the nucleotide sequences of the N (nucleocapsid)-gene of the hSARS virus. The present method eliminates false negative results and provides increased sensitivity for the assay. The invention also discloses the S (spike)-gene of the hSARS virus. The invention further relates to the deduced amino acid sequences of the N-gene and S-gene products of the hSARS virus and to the use of the N-gene and S-gene products in diagnostic methods. The invention further encompasses diagnostic assays and kits comprising antibodies generated against the N-gene or S-gene product.Type: GrantFiled: March 24, 2004Date of Patent: June 16, 2009Assignee: The University of Hong KongInventors: Joseph S. M. Peiris, Kwok Yung Yuen, Lit Man Poon, Yi Guan, Kwok Hung Chan, John M. Nicholls, Frederick C. Leung
-
Patent number: 7375202Abstract: The present invention relates to an isolated novel virus causing Severe Acute Respiratory Syndrome (SARS) in humans (“hSARS virus”). The hSARS virus is identified to be morphologically and phylogenetically similar to known member of Coronaviridae. The present invention provides the complete genomic sequence of the hSARS virus. Furthermore, the invention provides the nucleic acids and peptides encoded by and/or derived from the hSARS virus and their use in diagnostic methods and therapeutic methods, including vaccines. In addition, the invention provides chimeric or recombinant viruses encoded by said nucleotide sequences and antibodies immunospecific to the polypeptides encoded by the nucleotide sequences.Type: GrantFiled: March 24, 2004Date of Patent: May 20, 2008Assignee: The University of Hong KongInventors: Joseph S. M. Peiris, Kwok Yung Yuen, Lit Man Poon, Yi Guan, Kwok Hung Chan, John M. Nicholls, Frederick C. Leung